Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS

This publication has 18 references indexed in Scilit:

• Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma
  Medical Oncology, 2018
• Association of pharmacokinetics of axitinib with treatment outcome and adverse events in advanced renal cell carcinoma patients.
  Journal of Clinical Oncology, 2015
• Axitinib plasma pharmacokinetics and ethnic differences
  Investigational New Drugs, 2015
• Method Transfer, Partial Validation, and Cross Validation: Recommendations for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team
  The AAPS Journal, 2014
• Contemporary incidence and mortality rates of kidney cancer in the United States
  Canadian Urological Association Journal, 2014
• Pharmacokinetics, Metabolism, and Excretion of [14C]Axitinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Humans
  Drug Metabolism and Disposition, 2014
• Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
  The Journal of Clinical Pharmacology, 2013
• Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma
  Clinical Medicine Insights: Oncology, 2013
• Age-Adjusted Incidence, Mortality, and Survival Rates of Stage-Specific Renal Cell Carcinoma in North America: A Trend Analysis
  European Urology, 2011
• Strategies for the Assessment of Matrix Effect in Quantitative Bioanalytical Methods Based on HPLC−MS/MS
  Analytical Chemistry, 2003